Celcuity (NASDAQ:CELC) Given “Buy” Rating at HC Wainwright

Celcuity (NASDAQ:CELC)‘s stock had its “buy” rating reissued by HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga reports. They currently have a $27.00 price objective on the stock. HC Wainwright’s target price points to a potential upside of 167.06% from the company’s previous close.

Separately, Needham & Company LLC increased their price objective on Celcuity from $23.00 to $29.00 and gave the stock a “buy” rating in a report on Thursday, February 6th. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $30.17.

Celcuity Trading Down 1.3 %

Celcuity stock opened at $10.11 on Tuesday. Celcuity has a 12 month low of $8.53 and a 12 month high of $22.04. The company has a quick ratio of 10.36, a current ratio of 10.35 and a debt-to-equity ratio of 0.65. The stock has a market cap of $375.38 million, a P/E ratio of -3.87 and a beta of 0.65. The company’s fifty day simple moving average is $11.18 and its 200-day simple moving average is $12.91.

Celcuity (NASDAQ:CELC) last issued its earnings results on Monday, March 31st. The company reported ($0.85) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.13). As a group, sell-side analysts forecast that Celcuity will post -2.62 EPS for the current fiscal year.

Institutional Trading of Celcuity

Several large investors have recently modified their holdings of CELC. Summit Investment Advisors Inc. grew its stake in shares of Celcuity by 49.5% in the fourth quarter. Summit Investment Advisors Inc. now owns 3,421 shares of the company’s stock worth $45,000 after acquiring an additional 1,132 shares during the last quarter. Corebridge Financial Inc. boosted its stake in shares of Celcuity by 12.9% in the 4th quarter. Corebridge Financial Inc. now owns 16,256 shares of the company’s stock valued at $213,000 after purchasing an additional 1,858 shares in the last quarter. JPMorgan Chase & Co. grew its stake in Celcuity by 22.3% during the fourth quarter. JPMorgan Chase & Co. now owns 14,683 shares of the company’s stock worth $192,000 after buying an additional 2,676 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Celcuity by 16.2% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,725 shares of the company’s stock worth $258,000 after acquiring an additional 2,756 shares during the last quarter. Finally, Barclays PLC grew its holdings in shares of Celcuity by 6.7% during the fourth quarter. Barclays PLC now owns 57,199 shares of the company’s stock worth $749,000 after purchasing an additional 3,594 shares during the last quarter. 63.33% of the stock is owned by institutional investors.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.